125 related articles for article (PubMed ID: 21252750)
1. Prevention of learning deficit in a Down syndrome model.
Incerti M; Toso L; Vink J; Roberson R; Nold C; Abebe D; Spong CY
Obstet Gynecol; 2011 Feb; 117(2 Pt 1):354-361. PubMed ID: 21252750
[TBL] [Abstract][Full Text] [Related]
2. Reversal of alcohol-induced learning deficits in the young adult in a model of fetal alcohol syndrome.
Incerti M; Vink J; Roberson R; Wood L; Abebe D; Spong CY
Obstet Gynecol; 2010 Feb; 115(2 Pt 1):350-356. PubMed ID: 20093910
[TBL] [Abstract][Full Text] [Related]
3. Prenatal treatment prevents learning deficit in Down syndrome model.
Incerti M; Horowitz K; Roberson R; Abebe D; Toso L; Caballero M; Spong CY
PLoS One; 2012; 7(11):e50724. PubMed ID: 23209818
[TBL] [Abstract][Full Text] [Related]
4. Prenatal NAP+SAL prevents developmental delay in a mouse model of Down syndrome through effects on N-methyl-D-aspartic acid and gamma-aminobutyric acid receptors.
Vink J; Incerti M; Toso L; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2009 May; 200(5):524.e1-4. PubMed ID: 19327737
[TBL] [Abstract][Full Text] [Related]
5. Prevention of developmental delays in a Down syndrome mouse model.
Toso L; Cameroni I; Roberson R; Abebe D; Bissell S; Spong CY
Obstet Gynecol; 2008 Dec; 112(6):1242-1251. PubMed ID: 19037032
[TBL] [Abstract][Full Text] [Related]
6. Understanding the mechanism of learning enhancement: NMDA and GABA receptor expression.
Toso L; Johnson A; Bissell S; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2007 Sep; 197(3):267.e1-4. PubMed ID: 17826414
[TBL] [Abstract][Full Text] [Related]
7. D-SAL and NAP: Two Peptides Sharing a SIP Domain.
Gozes I; Sragovich S; Schirer Y; Idan-Feldman A
J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081
[TBL] [Abstract][Full Text] [Related]
8. Treatment with neuropeptides attenuates c-fos expression in a mouse model of fetal alcohol syndrome.
Incerti M; Vink J; Roberson R; Abebe D; Spong CY
Am J Perinatol; 2010 Oct; 27(9):743-8. PubMed ID: 20446212
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective peptides prevent some alcohol-induced alteration in gamma-aminobutyric acid A-beta3, which plays a role in cleft lip and palate and learning in fetal alcohol syndrome.
Toso L; Roberson R; Abebe D; Spong CY
Am J Obstet Gynecol; 2007 Mar; 196(3):259.e1-5. PubMed ID: 17346546
[TBL] [Abstract][Full Text] [Related]
10. Prevention of the alcohol-induced changes in brain-derived neurotrophic factor expression using neuroprotective peptides in a model of fetal alcohol syndrome.
Incerti M; Vink J; Roberson R; Benassou I; Abebe D; Spong CY
Am J Obstet Gynecol; 2010 May; 202(5):457.e1-4. PubMed ID: 20452488
[TBL] [Abstract][Full Text] [Related]
11. Prevention of alcohol-induced learning deficits in fetal alcohol syndrome mediated through NMDA and GABA receptors.
Toso L; Poggi SH; Roberson R; Woodard J; Park J; Abebe D; Spong CY
Am J Obstet Gynecol; 2006 Mar; 194(3):681-6. PubMed ID: 16522397
[TBL] [Abstract][Full Text] [Related]
12. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N; Pikman R; Giladi E; Gozes I
Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective peptides influence cytokine and chemokine alterations in a model of fetal alcohol syndrome.
Roberson R; Kuddo T; Benassou I; Abebe D; Spong CY
Am J Obstet Gynecol; 2012 Dec; 207(6):499.e1-5. PubMed ID: 23174390
[TBL] [Abstract][Full Text] [Related]
14. Learning enhancement with neuropeptides.
Toso L; Endres M; Vink J; Abebe DT; Brenneman DE; Spong CY
Am J Obstet Gynecol; 2006 Apr; 194(4):1153-8; discussion 1158-9. PubMed ID: 16580319
[TBL] [Abstract][Full Text] [Related]
15. Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss.
Zhou FC; Fang Y; Goodlett C
Alcohol Clin Exp Res; 2008 Aug; 32(8):1361-71. PubMed ID: 18565153
[TBL] [Abstract][Full Text] [Related]
16. The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome.
Poggi SH; Goodwin K; Hill JM; Brenneman DE; Tendi E; Schinelli S; Abebe D; Spong CY
Am J Obstet Gynecol; 2003 Sep; 189(3):790-3. PubMed ID: 14526315
[TBL] [Abstract][Full Text] [Related]
17. Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation.
Sahir N; Brenneman DE; Hill JM
J Mol Neurosci; 2006; 30(3):329-40. PubMed ID: 17401158
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABA
Duchon A; Gruart A; Albac C; Delatour B; Zorrilla de San Martin J; Delgado-García JM; Hérault Y; Potier MC
Br J Pharmacol; 2020 Mar; 177(5):1106-1118. PubMed ID: 31652355
[TBL] [Abstract][Full Text] [Related]
19. N-methyl-D-aspartate subunit expression during mouse development altered by in utero alcohol exposure.
Toso L; Poggi SH; Abebe D; Roberson R; Dunlap V; Park J; Spong CY
Am J Obstet Gynecol; 2005 Oct; 193(4):1534-9. PubMed ID: 16202752
[TBL] [Abstract][Full Text] [Related]
20. Protective peptides that are orally active and mechanistically nonchiral.
Brenneman DE; Spong CY; Hauser JM; Abebe D; Pinhasov A; Golian T; Gozes I
J Pharmacol Exp Ther; 2004 Jun; 309(3):1190-7. PubMed ID: 15007105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
